$0.83
4.93% yesterday
Nasdaq, Apr 07, 10:10 pm CET
ISIN
US72941H4002
Symbol
PSTV
Sector
Industry

Plus Therapeutics Inc Stock price

$0.83
-0.74 47.26% 1M
-0.58 41.28% 6M
-0.32 28.00% YTD
-1.06 56.19% 1Y
-13.87 94.37% 3Y
-22.72 96.48% 5Y
-151,874.17 100.00% 10Y
Nasdaq, Closing price Mon, Apr 07 2025
+0.04 4.93%
ISIN
US72941H4002
Symbol
PSTV
Sector
Industry

Key metrics

Market capitalization $14.08m
Enterprise Value $13.84m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.38
P/S ratio (TTM) P/S ratio 2.42
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 18.54%
Revenue (TTM) Revenue $5.82m
EBIT (operating result TTM) EBIT $-14.70m
Free Cash Flow (TTM) Free Cash Flow $-10.70m
Cash position $3.61m
EPS (TTM) EPS $-2.06
P/E forward negative
P/S forward 1.95
EV/Sales forward 1.92
Short interest 16.07%
Show more

Is Plus Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Plus Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Plus Therapeutics Inc forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Plus Therapeutics Inc forecast:

Buy
100%

Financial data from Plus Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
5.82 5.82
19% 19%
100%
- Direct Costs 0.85 0.85
13% 13%
15%
4.97 4.97
19% 19%
85%
- Selling and Administrative Expenses 8.24 8.24
17% 17%
142%
- Research and Development Expense 11 11
9% 9%
182%
-14 -14
10% 10%
-238%
- Depreciation and Amortization 0.85 0.85
13% 13%
15%
EBIT (Operating Income) EBIT -15 -15
10% 10%
-252%
Net Profit -13 -13
3% 3%
-223%

In millions USD.

Don't miss a Thing! We will send you all news about Plus Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Plus Therapeutics Inc Stock News

Neutral
Seeking Alpha
11 days ago
Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q4 2024 Earnings Conference Call March 27, 2025 5:00 PM ET Company Participants Marc Hedrick - President and CEO Andrew Sims - CFO Conference Call Participants Edward Woo - Ascendiant Capital Sean Lee - H.C. Wainwright Operator Good afternoon, ladies and gentlemen.
Neutral
GlobeNewsWire
11 days ago
HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the fourth quarter and full year ended December 31, 2024, and provides an overview of recent and upcomi...
Neutral
GlobeNewsWire
19 days ago
REYOBIQ™ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM) HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) c...
More Plus Therapeutics Inc News

Company Profile

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. Its products include Rhenium NanoLiposome (RNL) and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.

Head office United States
CEO Marc Hedrick
Employees 21
Founded 1996
Website www.plustherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today